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Abstract
Introduction: Cardiovascular benefits and improved survival have resulted in statins becoming the
most prescribed drugs in USA. There is a small but significant risk of developing statin induced
rhabdomyolysis especially in combination with other lipid lowering medications for example fibrates
like Gemfibrozil.
Case presentation: We describe a case of an 82 year old male patient who developed
rhabdomyolysis while taking a combination of Simvastatin and Gemfibrozil and was successfully
managed with plasmapheresis.
Conclusion: There are only a few cases of rhabdomyolysis treated with plasmapheresis reported in
literature. Most of the case reports of using this technique in rhabdomyolysis have been from Asia,
Australia and Europe. We suggest that plasmapheresis may be considered as an option in severe life
threatening rhabdomyolysis.
Introduction
Acute rhabdomyolysis is a syndrome characterized by the
breakdown of skeletal muscle resulting in subsequent
release of intracellular contents into the circulatory system,
which can cause potentially lethal complications. These
contents include myoglobin, potassium, aldolase, lactate
dehydrogenase, creatine phosphokinase and glutamic
oxaloacetic transaminase.
Acute renal failure is one of the most common complica-
tions of rhabdomyolysis. HMG-CoA reductase inhibitors
are the most commonly prescribed lipid lowering medica-
tions.InduceddeficiencyofCo-enzymeQ,amitochondrial
and lipid membrane antioxidant and a cofactor in
mitochondrial ATP production has been proposed as the
possible cause for statin related muscle injury.
The traditional management of rhabdomyolysis induced
acute renal failure includes aggressive intravenous fluid
resuscitation, use of mannitol and bicarbonate is also
notable for reducing risk of ARF. However evidence has
not really proven benefit of these measures over use of
intravenous fluid administration. Standard hemodialysis
techniques have limited ability to remove circulating
myoglobin (proposed reasons for this, see under
Discussion).
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pheresis in rhabdomyolysis. The available literature is
detailed/ reviewed in the Discussion section of this article.
Case presentation
An 82 year old white male was admitted with 10 day
history of severe, continuous myalgia and proximal
muscle weakness. He denied vigorous physical exercise,
heat exposure, alcohol or recreational drug abuse. He
reports no other specific complaints.
His medications Simvastatin 80 mg qhs, Metoprolol
extended release 25 mg once daily, Hydrocodone/Acet-
aminophen 7.5/500 mg p.r.n. for pain, cyclobenzaprine
10 mg t.i.d. p.r.n. for muscle spasms and lisinopril 10 mg
once daily. He had been on simvastatin for many years,
pertinent to note that Gemfibrozil 600 mg b.i.d. had been
started a monthago. Hereports nosignificant food or drug
allergies.
Past medical/surgical history of viral cardiomyopathy
5 years back, migraines, obstructive sleep apnea, shoulder
and foot surgery, appendecectomy, Cervical and lumbo-
sacral spondylosis status post laminectomy , BPH status
post transurethral resection of prostate and non melanotic
skin cancer. Family history significant for hypertension.
On admission serum K 5.9, Na 132, BUN 73, Cr 2.2,
albumin 2.7, chloride 98, CO2 21, CBC was within
normal limits (Table 1) CK was 41368 on presentation
(n=35-232 U/L), ALT was 1293 (n=30-65U/L) AST 1439
(n=15-37) phosphorus 5.4, calcium 9.5. UA showed 3+
occult blood with only 4-10 RBCs per high power field.
Acute renal failure and abnormal liver function tests
secondary to rhabdomyolysis was diagnosed. Simvastatin
and Gemfibrozil were stopped and he was started on
aggressive alkaline intravenous fluid resuscitation. In light
of the elevated potassium and ARF, ACE-I was also
stopped.
By hospital day 4 creatinine kinase rose to 86400, BUN 82,
Cr 2, ALT 930 and AST 1326. UA showed 3+occult blood
with no red blood cells on microscopic examination.
He became oliguric; plasmapheresis with one and a half
volume replacement with albumin was started at this
point in addition to hemodialysis. The patient received
plasmapheresis daily for 5 days in addition to
hemodialysis
Patient was discharged to Physical Medicine and Rehabi-
litation at Day 30, he remained off dialysis and
plasmapheresis and was discharged in stable ambulatory
status.
Approximately 6 months after this episode all laboratory
parameters were within normal limits, he remained at
baseline health as well as functional status. Approximately
4 years after this episode, at his last outpatient nephrology
clinic visit all his laboratory values remain within normal
limits and he maintains baseline health and functional
status.
Omega-3 fish oil supplements, diet and lifestyle changes
were used to treat his abnormal lipid profile, statins and
fibrates were avoided due to this episode and also due to
patient’s desire that he not be treated with either of the two
medications. It is pertinent to note that his last lipid
profile meets ATP III guideline goals.
Discussion
Acute rhabdomyolysis is characterized by the breakdown
of skeletal muscles resulting in subsequent release of
intracellular contents into the circulatory system, which
can cause potentially lethal complications. These contents
include myoglobin, potassium, aldolase, lactate dehydro-
genase, creatine phosphokinase and glutamic -oxaloacetic
transaminase.
A potentially lethal complication of rhabdomyolysis is
acute renal failure. 3 hydroxy-3- methyl glutaryl coenzyme
Table 1. Patient’s laboratory values from day 1 to day 30
Day Creatinine
Kinase
BUN SGPT(ALT) SGOT(AST) Albumin Calcium Creatinine Potassium
1 41368 73 1293 1439 2.7 9.5 2.2 5.9
2 26477 70 1441 1660 2.3 8.7 2.2 5.2
3 45504 62 1585 1842 2.1 8.3 1.8 3.8
4* 86400 82 930 1326 3.3 7.2 2.6 3.6
5 85578 105 983 996 2.9 5.5 2.3 4.1
6 29698 56 839 769 2.9 6.2 2.4 3.8
7 27291 76 610 410 2.6 6.6 3.6 4.0
8** 10330 70 765 339 2.5 8.1 4.2 4.7
15 131 60 188 34 3.2 9.1 3.6 3.6
30 96 14 13 17 3.4 8.9 1.9 4.4
Red denotes higher than normal and blue denotes lower than normal values.
*plasmapheresis initiated, **plasmapheresis discontinued.
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commonly prescribed drugs in the USA. Upto 5% of
patients taking statins may have muscle related com-
plaints, typically myalgias; however myositis and rhabdo-
myolysis do occur.
Induced deficiency of Co-enzyme Q which is a mitochon-
drial and lipid membrane antioxidant and cofactor in
mitochondrial ATP production has been proposed as a
possible cause for statin related muscle injury.
When combined with gemfibrozil, all statins except
fluvastatin have been associated with reports of rhabdo-
myolysis, it is pertinent to this case that gemfibrozil was
added to simvastatin resulting in rhabdomyolysis [1-3].
Although the reason for the increased risk of rhabdomyo-
lysis with combination therapy is not clear, a possible
explanation is that gemfibrozil increases serum concentra-
tion of active statin acids, the risk of statin induced
myopathy is enhanced in the elderly [3], note that this
patient is 82 years old. Risk of ARF after rhabdomyolysis
has been estimated to be between 17 % and 35 % [4,5].
Management of myoglobinuric acute renal failure includes
aggressive intravenous fluid (typically alkaline) adminis-
tration to restore the hypovolemia. While mannitol and
bicarbonate are considered standard care in preventing
acute renal failure in these patients the available evidence
suggests that that there is no benefit over and above
aggressive fluid resuscitation [5,6].
The techniques and devices used for classic dialytic
technique have displayed a limited capacity for the
removal of circulating myoglobin [6]; myoglobin’s non-
spherical shape and electrical charge make it a solute with
an Einstein-Stokes radius greater than expected. This
results in low diffusion coefficient, requiring transport by
convection; myoglobin also possesses a steric magnitude
that is likely to be rejected by most high flux dialyzer
membrane pores.
Literature containing use of plasmapheresis in rhabdo-
myolysis is scarce and anecdotal.
Ronco [6] reported that attempts to use plasmapheresis in
myoglobinemia have resulted in higher sieving coeffi-
cients, but notes limitations due to low volume exchanges.
Kuroda et al [7] reported successful treatment by plasma
exchange of acute renal failure, DIC and multiorgan
damage associated with extensive muscle damage.
Paaske et al [8] reports on a patient with acute compart-
ment syndrome causing rhabdomyolysis, ARF, and was
successfully managed with plasmapheresis.
Cornellisen et al [9] evaluated 4 patients with rhabdo-
myolysis. The results showed that a single 2 liter plasma
exchange has no beneficial effects in the treatment of
patients with rhabdomyolysis. It is prudent to note only
one plasma exchange was done; all other case reports have
used multiple daily exchanges.
Yang et al [10] used plasma exchange in a case of
rhabdomyolysis complicated with increased serum Beza-
fibrate level .They advocated that Bezafibrate being highly
protein bound is unlikely to be cleared by hemodialysis .
They suggested that plasma exchange is safe and effective
in addition to supportive care for rhabdomyolysis
associated with excessive Bezafibrate.
Conclusion
Rhabdomyolysis is a potentially life threatening condition
that should be suspected in all patients on statins
presenting with myalgias. Patients on combination
therapy with other medications like Gemfibrozil have a
higher risk of developing it.
We learn from this case that physicians should be vigilant
regarding this potentially lethal adverse effect, laboratory
follow up should be maintained on liver function and
muscle enzyme levels. Physicians must ensure that the
patient is appropriately educated about potential adverse
reactions including rhabdomyolysis before prescribing
these medications. A well informed patient can notify
his physician in a timely fashion, thereby potentially
avoiding a life-threatening complication.
In this case especially keeping in mind the steady
reduction in toxic muscle enzyme levels with use of
plasmapheresis , we recommend that plasma exchange be
considered in cases of severe rhabdomyolysis and acute
renal failure not responding to the standard medical
management of intravenous fluid resuscitation.
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